Morgan Stanley lowers the target price of GENSCRIPT BIO (01548) to 16.5 Hong Kong dollars and maintains a "buy" rating.
After Kingsway Group Biotechnology (01548) issued a profit warning, its earnings forecast for 2026 to 2030 has been lowered by 1% to 13%, and the corresponding target price has been lowered from HK$18.3 to HK$16.5. The "buy" rating is maintained.
Morgan Stanley released a research report stating that after GENSCRIPT BIO (01548) issued a profit warning, its earnings forecast for 2026 to 2030 has been lowered by 1% to 13%. The corresponding target price has been reduced from 18.3 Hong Kong dollars to 16.5 Hong Kong dollars, and the "buy" rating has been maintained.
Related Articles
Jiangsu Hengrui Pharmaceuticals(600276.SH): Injection SHR-9803 obtains drug clinical trial approval letter.
YUEXIU REIT (00405) announced its performance for 2025, with a net property income of approximately 1.284 billion yuan, a year-on-year decrease of 11.2%.
WKK INTL (HOLD) (00532): Taiwan International Port Corporation's annual consolidated net profit after tax is NT$177 million, an increase of approximately 15.2% year-on-year.
Jiangsu Hengrui Pharmaceuticals(600276.SH): Injection SHR-9803 obtains drug clinical trial approval letter.
YUEXIU REIT (00405) announced its performance for 2025, with a net property income of approximately 1.284 billion yuan, a year-on-year decrease of 11.2%.
WKK INTL (HOLD) (00532): Taiwan International Port Corporation's annual consolidated net profit after tax is NT$177 million, an increase of approximately 15.2% year-on-year.
RECOMMEND
“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026
Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026
U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026
